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SHORT COMMUNICATION
CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables
both in vitro and in vivo KRT12 mutation-speciﬁc targeting
DG Courtney1, JE Moore1,2, SD Atkinson1, E Maurizi1, EHA Allen3, DML Pedrioli3, WHI McLean3, MA Nesbit1 and CBT Moore1
CRISPR/Cas9-based therapeutics hold the possibility for permanent treatment of genetic disease. The potency and speciﬁcity of this
system has been used to target dominantly inherited conditions caused by heterozygous missense mutations through inclusion of
the mutated base in the short-guide RNA (sgRNA) sequence. This research evaluates a novel approach for targeting heterozygous
single-nucleotide polymorphisms (SNPs) using CRISPR/Cas9. We determined that a mutation within KRT12, which causes
Meesmann’s epithelial corneal dystrophy (MECD), leads to the occurrence of a novel protospacer adjacent motif (PAM). We
designed an sgRNA complementary to the sequence adjacent to this SNP-derived PAM and evaluated its potency and allele
speciﬁcity both in vitro and in vivo. This sgRNA was found to be highly effective at reducing the expression of mutant KRT12 mRNA
and protein in vitro. To assess its activity in vivo we injected a combined Cas9/sgRNA expression construct into the corneal stroma
of a humanized MECD mouse model. Sequence analysis of corneal genomic DNA revealed non-homologous end-joining repair
resulting in frame-shifting deletions within the mutant KRT12 allele. This study is the ﬁrst to demonstrate in vivo gene editing of a
heterozygous disease-causing SNP that results in a novel PAM, further highlighting the potential for CRISPR/Cas9-based
therapeutics.
Gene Therapy (2016) 23, 108–112; doi:10.1038/gt.2015.82; published online 20 August 2015
INTRODUCTION
The discovery of a simple endogenous bacterial system for
catalytically cleaving double-stranded DNA has revolutionized
the ﬁeld of therapeutic gene editing. The Type II Clustered
Regularly Interspaced Short Palindromic Repeats (CRISPR)/ CRISPR
associated protein 9 (Cas9) is a programmable RNA guided
endonuclease, which has recently been shown to be effective at
gene editing in mammalian cells.1 This highly speciﬁc and efﬁcient
RNA-guided DNA endonuclease may be of therapeutic importance
in a range of genetic diseases. The CRISPR/Cas9 system relies on a
single catalytic protein, Cas9 that is guided to a speciﬁc DNA
sequence by 2 RNA molecules; the tracrRNA and the crRNA.1
Combination of the tracrRNA/crRNA into a single guide RNA
molecule (sgRNA)2,3 has led to the rapid development of gene
editing tools potentially speciﬁc for any target within the genome.
Through the substitution of a 20-nucleotide sequence within the
sgRNA, to one complimentary to a chosen target, a highly speciﬁc
system can be generated in a matter of days. One caveat of this
system is that the endonuclease requires a protospacer adjacent
motif (PAM), located immediately 3′ of the sgRNA binding site.
This PAM sequence is an invariant part of the DNA target but not
present in the sgRNA,2,3 while its absence at the 3′ end of the
genomic target sequence results in the inability of the Cas9 to
cleave the DNA target.4
The introduction of this technology into a therapeutic setting
raised questions over its potential allele-speciﬁcity. However, as
previously demonstrated by Smith et al. and Yoshimi et al. in
animal models, simply altering a single nucleotide within the
20-nucleotide sequence in the sgRNA the CRISPR/Cas9 system
renders it unable to bind and cleave the target site.5,6 This offers
the potential of targeting disease causing dominant-negative
single-nucleotide polymorphisms (SNPs) to disable the mutant
allele, whereas expression of the wild-type allele would remain
unaffected.
Using an alternative approach, this study examined the
potential of an allele-speciﬁc CRISPR/Cas9 system for hereditary
corneal dystrophies, speciﬁcally focusing on a dominant-negative
mutation in KRT12 (encoding keratin 12, K12), Leu132Pro
(c. 395 T4C), which results in Meesmann’s epithelial corneal
dystrophy (MECD; OMIM:122100).7 Interestingly, this mutation
results in the manifestation of a novel Streptococcus pyogenes
PAM, not present in the wild-type allele. By incorporating the
20 nucleotides 5′ of this novel PAM into an sgRNA, we sought to
establish whether allele-speciﬁc cleavage of the mutant allele
could be induced. In a heterozygous cell, this double-strand break
would either lead to non-homologous end joining (NHEJ), which
frequently results in a frameshift and the manifestation of a
premature stop codon, or homology-directed repair where
recombination with the wild-type allele directs repair of the
mutant sequence. In the case of KRT12, both outcomes could be
considered a therapeutic success; either expression of the
dominant-negative mutant K12 protein is abolished by NHEJ,
which is tolerated, as KRT12 has been shown not to demonstrate
haploinsufﬁciency,8 or the mutant allele is repaired by homology-
directed repair, resulting in the repair of the K12-Leu132Pro allele.
Through use of techniques adapted from our previous research
identifying therapeutic allele-speciﬁc short interfering RNAs,7,9–11
this Cas9-based gene-editing system was found to be potent and
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allele speciﬁc. This study constitutes the ﬁrst description of allele-
speciﬁc CRISPR/Cas9 gene editing at a novel PAM created by a
disease-causing heterozygous SNP.
RESULTS
Construction of a KRT12-speciﬁc sgRNA
An analysis of the sequence changes that result from MECD-
causing KRT12 missense mutations revealed that the L132P
mutation7 that causes the severe form of MECD coincidentally
results in the generation of a novel PAM site (AAG4AGG). An
sgRNA (sgK12LP) complementary to the sequence 20 nucleotides
adjacent to the 5′-end of the novel PAM site generated by the
KRT12 L132P mutation was designed and assessed for potential off
targets using the ‘Optimised CRISPR Design Tool’ provided online
by the Zhang lab, MIT 2013, (Figure 1, red). The sgRNA was
calculated as having a score of 66% using this system, where a
score 450% is deemed to be of high quality with a limited
number of predicted possible off targets.
Assessment of sgK12LP allele speciﬁcity and potency in vitro
The allele-speciﬁcity and potency of sgK12LP was assessed in vitro,
in HEK AD293 cells, using exogenous expression constructs for
wild-type and mutant K12. Allele speciﬁcity was ﬁrst determined
using a dual-luciferase reporter assay (Figure 2a). Fireﬂy luciferase
activity was found to be signiﬁcantly decreased in cells expressing
either K12WT-Luc or K12LP-Luc and treated with sgK12. A potent
and allele-speciﬁc reduction of ﬁreﬂy luciferase activity was
observed in cells treated with sgK12LP. In cells expressing
K12LP-Luc, a reduction of 73.4 ± 2.7% (Po0.001) was observed
(Figure 2a). This allele-speciﬁc and potent knockdown was also
observed by western blotting, in cells expressing either K12WT-HA
or K12LP-HA (Figure 2b; image representative of four blots) and
quantiﬁcation by densitometry revealed a signiﬁcant reduction of
32% in K12LP-HA protein by sgK12LP in comparison with K12WT-
HA protein (Po0.05). In cells treated with sgK12, both wild-type
and mutant K12 protein was found to have decreased, whereas in
those treated with sgK12LP there appeared to be no effect on
expression of the wild-type protein but a signiﬁcant knockdown of
the mutant K12 protein (Figure 2b).
To support this data, observed at the protein level, quantitative
reverse transcriptase-PCR and pyrosequencing were carried out to
determine allele speciﬁcity and potency at the mRNA level. In cells
expressing both wild-type and mutant K12 simultaneously
(in a 1:1 expression ratio) and treated with each of the three
test Cas9/sgRNA expression constructs (NSC, K12 and K12LP),
quantitative reverse transcriptase-PCR was used to determine
knockdown of total K12 mRNA (Figure 2c). A potent reduction of
73.1 ± 4.2% (Po0.001) of total K12 mRNA was observed in sgK12-
treated cells, with a lesser reduction of 52.6 ± 7.0% (Po0.01)
measured in sgK12LP-treated cells (Figure 2c). Pyrosequencing
was used to determine the intracellular proportion of the
remaining mature mRNA species after treatment with these
sgRNAs (Figure 2d). Proportions of mRNA were calculated as
‘percentage of K12-L132P’/percentage of K12-WT’. Cells treated
with sgNSC were normalized to 1, assuming a ratio of 1:1 between
mutant and wild-type K12 mRNA. In cells tested with sgK12, a K12
mutant mRNA proportion of 0.89 ± 0.03 was observed, but the
difference to the NSC control was not signiﬁcant (Po0.14). In
those cells treated with sgK12LP, a K12 mutant mRNA proportion
of 0.28 ± 0.02 was detected and was signiﬁcantly altered in
comparison with the sgNSC-treated cells (Po0.001) (Figure 2d).
Determination of the efﬁcacy of sgRNA-K12LP in vivo
Intrastromal injection of the Cas9-GFP construct resulted in the
presence of green ﬂuorescent protein (GFP) protein in the corneal
epithelium at 24 h post injection (Figure 3a). Transient expression
of GFP was found up to 48 h post injection. Following intrastromal
injection of either the sgK12LP or sgNSC expression constructs
into K12-L132P humanized heterozygous mice and an incubation
period of 48 h, mice were euthanized and genomic DNA (gDNA)
prepared from the corneas. gDNA from the corneas of four
sgK12LP- or sgNSC-treated animals was pooled and PCR
ampliﬁcation of exon 1 of the humanized K12-L132P gene, cloning
and sequencing was performed. Of 10 clones established from
gDNA of eyes treated with sgNSC, the K12-L132P sequence
remained intact in all 10. Thirteen individual clones from sgK12LP-
treated eyes were sequenced; eight were found to contain an
unaltered KRT12 L132P human sequence, whereas ﬁve clones
demonstrated NHEJ around the predicted cleavage site of the
Cas9/sgK12LP complex (Figure 3b). In one clone (1), an insertion of
1 nucleotide was found, with a deletion of 32 nucleotides. Large
deletions of up to 53 nucleotides were observed in vivo (clone 5).
Of these 5 clones, 4 contained deletions (clones 1 and 3–5) that
are predicted to result in a frameshift that would lead to the
occurrence of an early stop codon. The top 2 predicted exonic off-
target sites of sgK12LP in mouse were also assessed using this
method. Ten clones were sequenced for each target and none
were found to have undergone nonspeciﬁc cleavage.
DISCUSSION
Since the discovery of the bacterial CRISPR/Cas9 system and its
proven efﬁcacy in mammalian cells, a number of studies have
demonstrated the potential therapeutic value of this system for a
wide range of genetic diseases.12–14 This technology has been
further used in an allele-speciﬁc manner, demonstrating the
potential of the CRISPR/Cas9-based system for treating dominant
hereditary conditions.5,6 Within this study, we aimed to develop an
allele-speciﬁc genome-editing system employing S. pyogenes Cas9
for the KRT12-L132P mutation that leads to the onset of MECD.
However, this research took a novel approach in targeting a
heterozygous mutation that results in the occurrence of a novel
PAM site in the mutant allele, caused by the single base change at
position 395 (T4C). The aim of this study was to determine
whether targeting the sequence adjacent to this PAM site could
result in potent and allele-speciﬁc cleavage of the KRT12-L132P
allele, establishing the potential for therapeutic utilization of these
SNP-derived PAMs for dominantly inherited diseases.
An sgRNA adjacent to this SNP-derived PAM was assessed by
co-transfection of Cas9/sgRNA expression constructs, with exo-
genous reporter constructs in mammalian cells. In the event of
Figure 1. Design of sgRNAs for targeting wild-type and mutant K12
alleles. An sgRNA to use the SNP-derived PAM found on the K12-
L132P allele was designed (red). This PAM is absent from the wild-
type allele. A second sgRNA to target both wild-type and mutant
K12 alleles (green) was also designed and used as a positive control.
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sgRNA recognition of its target site and Cas9-mediated cleavage
of the exogenous luciferase reporter construct, luciferase mRNA
transcription is disrupted and the plasmid becomes functionally
silent. Neither NHEJ nor homology-directed repair need occur to
observe this effect. Through utilization of dual-luciferase reporter
assays, western blotting, quantitative reverse transcriptase-PCR
and pyrosequencing the expression levels of wild-type and
mutant K12 were quantiﬁed at both the mRNA and protein level.
The Cas9/sgRNA complex using the SNP-derived PAM was
found to be highly potent, similar to that of a positive control
KRT12 sgRNA common to both wild-type and mutant alleles, and
allele-speciﬁc, as demonstrated by no observable knockdown of
wild-type K12 expression.
To evaluate the targeting ability of the Cas9/sgRNA complex
in vivo and to identify functional knockout of the mutant allele by
NHEJ, a mouse model heterozygous for the human KRT12-L132P
allele was injected intrastromally with the allele-speciﬁc Cas9/
sgRNA expression construct. Corneal gDNA was extracted and the
human KRT12-L132P allele was PCR ampliﬁed, cloned and
sequenced. Of the clones sequenced, 38.5% were found to have
undergone NHEJ in vivo. Deletions ranging from 18 to 53
nucleotides were observed. As previous research into K12 has
demonstrated, a 50% reduction in the expression of the mutant
allele would sufﬁce in alleviating the phenotype,15 whereas
ablation of one KRT12 allele does not negatively affect corneal
integrity.8 We will endeavor to increase the targeting efﬁciency of
this system through methods including in-vivo electroporation.16
These studies will also investigate the corneal integrity of
heterozygous mice, having undergone Cas9-mediated NHEJ, over
a prolonged period of time.
This research demonstrates the potential for exploitation of
these SNP-derived PAMs in the development of personalized
therapeutics for dominantly inherited conditions. A review of
dystrophic mutations in KRT3, KRT12, TGFBI and COL8A2 showed
that of the 76 known missense mutations, 27 (36%) resulted in the
manifestation of a novel PAM (Supplementary Table S1), again
Figure 2. Evaluation of allele speciﬁcity and potency of sgK12LP using exogenous constructs. Exogenous expression constructs for wild-type
and mutant K12 were employed to test the allele-speciﬁcity and potency of sgK12LP. (a) A dual luciferase assay demonstrated the allele-
speciﬁcity of the sgK12LP plasmid, whereas potency was shown to be comparable to that of the sgK12 construct. N= 8 (b) Western blotting
further demonstrated these attributes with a noticeable reduction in K12-L132P protein in cells treated with sgK12LP in comparison with cells
treated but expressing K12 wild-type protein. β-Actin was used as a loading control. (c) Quantitative reverse transcriptase-PCR for total K12 in
cells expressing both wild-type and mutant alleles demonstrated a knockdown in mRNA expression. N= 4 (d) Allele proportions of this mRNA
knockdown were then quantiﬁed by pyrosequencing, conﬁrming an allele knockdown of the mutant allele in cells co-expressing both KRT12
alleles and treated with sgK12LP. N= 4, *Po0.05, **Po0.01, ***Po0.001.
Figure 3. Demonstration of sgK12LP-induced NHEJ in vivo. GFP expression was observed in the corneal epithelium of mice at 24 h post
intrastromal injection, demonstrating the efﬁcacy of an intrastromal plasmid injection for transfecting the corneal epithelium (a; N= 2). No
GFP expression was observed 48 h post injection. Sequencing of the gDNA from human K12-L132P heterozygous mice injected with the
sgK12LP construct demonstrated large deletions and the induction of NHEJ due to cleavage of the KRT12-L132P allele. Of 13 clones
sequenced, 5 were found to have undergone NHEJ (b).
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supporting the potential to use these SNP-derived PAMs in the
advancement of novel gene therapies. Following genetic diag-
nosis, a personalized sgRNA expression vector can be designed
and synthesized in relation to a patient’s particular disease-
causing mutation within a matter of weeks. Within this study we
have focused on corneal dystrophies but the potential exists for
developing therapies for a wide range of heterozygous disease-
causing SNPs, whether to knockout the mutant allele, as
demonstrated here using NHEJ, or to repair the mutant allele,
using similar methods already published using homology-directed
repair.17
MATERIALS AND METHODS
Constructs
Three plasmids expressing Cas9 and an sgRNA were used
throughout all experiments. The non-targeting plasmid used was
pSpCas9(BB)-2A-Puro (PX459), a gift from Professor Feng Zhang
(Broad Institute, MIT; Addgene plasmid 48139).17 Following a
published protocol,17 the plasmid containing the sgRNA speciﬁc
to the K12-L132P allele was designed by annealing and cloning
the following 2 primers (Life Technologies, Paisley, UK): 5′-CAC
CGTAGGAAGCTAATCTATCATT-3′ and 5′-AAACAATGATAGATTAGC
TTCCTAC-3′ into pSpCas9(BB)-2A-Puro. This sgRNA corresponds to
the 20 nucleotides directly 3′ of the allele-speciﬁc PAM found on
the K12-L132P allele (Figure 1, red), hereafter named sgK12LP.
A Cas9/sgRNA plasmid to target both wild-type and mutant K12
sequences was constructed (Sigma, Gillingham, UK) and used as a
positive control (Figure 1, green).
Additional K12 expression constructs previously described7
were used to assess allele speciﬁcity and potency. Fireﬂy luciferase
plasmids with the full mRNA sequence for either K12-WT or
K12-L132P inserted 3′ of the stop codon, hereafter named as
K12WT-Luc and K12LP-Luc, respectively,7 and expression plasmids
for mature haemagglutinin (HA)-tagged K12-WT and K12-L132P
protein,10 with plasmids hereafter known as K12WT-HA and
K12LP-HA, respectively, were used. An expression construct for
Renilla luciferase (pRL-CMV, Promega, Southampton, UK) was used
for the dual-luciferase assay to normalize transfection efﬁciency.
Dual-luciferase assay
A dual-luciferase assay was used to quantify potency and allele-
speciﬁcity of the three test sgRNAs in exogenous constructs, using
methods adapted as previously described.9,11,18 In short, HEK
AD293 cells (Life Technologies) were transfected using Lipofecta-
mine 2000 (Life Technologies) with both K12WT-Luc or K12LP-Luc
expression constructs and sgNSC, sgK12 or sgK12LP constructs at
a ratio of 1:4. Cells were incubated for 72 h before being lysed and
the activities of both Fireﬂy and Renilla luciferase quantiﬁed. In all,
eight replicates were carried out for each transfection condition.
Western blotting
HA-tagged wild-type (K12WT-HA) and mutant (K12LP-HA) expres-
sion constructs7 were transiently co-transfected with each of the
sgRNAs at a ratio of 1:4 into HEK AD293 cells in duplicate using
Lipofectamine 2000 (Invitrogen), using similar methods as
previously described.9 Transfected cells were incubated for 72 h.
Expression of HA-tagged K12 and β-actin was analysed using a
rabbit polyclonal antibody to HA (Abcam, Cambridge, UK; ab9110,
1:2000) and a mouse monoclonal antibody to human β-actin
(Sigma, 1:15 000) using standard methods.9 Membranes were
incubated with a secondary horseradish peroxide-conjugated
polyclonal swine anti-rabbit antibody (DakoCytomation, Ely, UK) or
a horseradish peroxide-conjugated goat anti-mouse antibody
(DakoCytomation), respectively. Protein binding was detected by
standard chemiluminescence (Life Technologies). Densitometry
was performed using ImageJ,19 to quantify the band intensity of
the HA-tagged K12 (n= 4). This was normalized to the band
intensity of β-actin.
Quantitative real-time PCR
Transfections were carried out in the same manner as described
for western blotting; however, both K12WT-HA and K12LP-HA
were simultaneously transfected into cells. All transfections were
carried out in triplicate. Following transfection, cells were
incubated for 48 h and RNA extracted using the RNAeasy Plus
kit (Qiagen, Venlo, The Netherlands). Following cDNA conversion
of 500 ng of RNA (Life Technologies) quantitative real-time PCR
was performed to quantify levels of KRT12 mRNA. A KRT12 assay
was used (assay Id 140679; Roche, West Sussex, UK) alongside an
HPRT assay (assay ID 102079; Roche) and a GAPDH assay (assay ID
141139; Roche). Each sample was run in triplicate for each assay
and relative gene expression was calculated using the ΔΔCT
method.20 KRT12 expression levels were normalized against HPRT
and GAPDH, where expression of both reference genes was
deemed to be ‘stable’ across treatment groups, using the
BestKeeper software tool.21
Pyrosequencing
Using the same cDNA samples assessed by quantitative reverse
transcriptase-PCR, pyrosequencing was carried out to determine
the ratio of remaining K12-L132P mRNA to K12-WT mRNA, exactly
as described previously.10
KRT12 transgenic mouse
A C57 mouse model was obtained, with a human K12-L132P allele
knocked in to replace the endogenous mouse Krt12 coding
sequence (details on request). This allowed for the in-vivo
targeting of KRT12-L132P by the allele-speciﬁc sgRNA and Cas9.
Female heterozygous mice at 24 weeks old were used, where one
copy of the human K12-L132P allele and one copy of murine Krt12
were present. Standard PCR and Sanger dideoxynucleotide
sequencing was used to genotype the mice and conﬁrm
heterozygosity of the K12-L132P allele. Randomization of animals
was not required, as this study investigated the effect of treatment
on one cornea, whereas the other cornea of the same animal was
used as the negative control. Investigators were not blinded in this
study. All experimentation complied with ethical regulations and
was approved by the local ethics committee.
In-vivo intrastromal ocular injection
To achieve transient expression of the allele-speciﬁc sgRNA and
the Cas9, the sgK12LP plasmid was introduced into the corneal
stroma of the heterozygous knock-in mice by intrastromal ocular
injection, following previously described protocols.22 To assess this
delivery method, wild-type mice were ﬁrst injected with 4 μg of a
Cas9-GFP plasmid (pCas9D10A_GFP), a gift from Kiran Musunuru
(Addgene plasmid 44720). Mice were culled at 24, 48 and 72 h,
and corneas ﬁxed in 4% paraformaldehyde and processed using
standard histological procedures. Five-micrometre-thick sections
were cut, rehydrated and imaged by ﬂuorescent microscopy.
Mice were administered with general anaesthetic and a local
anaesthetic to the cornea. A qualiﬁed ophthalmologist injected
4 μg of sgK12LP or sgNSC plasmid diluted in a total of 3 μl
phosphate-buffered saline into the cornea of the right eye and the
left eye, respectively, of four mice. Mice were culled 48 h post
treatment.
Sequencing and determination of NHEJ
Once the mice were culled, the eyes were enucleated and the
corneas were dissected. gDNA was extracted using a DNA
CRISPR/Cas9 DNA cleavage at SNP-derived PAM
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extraction kit (Qiagen) and samples were pooled into two
treatment groups: sgK12LP and sgNSC. Samples underwent PCR
ampliﬁcation using the following two primers to amplify the
region around the K12-L132P mutation: 5′-ACACCCATCTTGCA
GCCTAT-3′ and 5′-AAAATTCCCAAAGCGCCTC-3′. PCR products
were gel puriﬁed and ligated into the CloneJet cloning vector
(Life Technologies) and were used to transform DH5α competent
cells (Life Technologies). A total of 13 clones were selected and
plasmid DNA prepared using a miniprep kit (Qiagen) following
manufacturer’s procedures. DNA from the 13 clones was then
sequenced (Department of Zoology, University of Oxford) using
the sequencing primers provided with the CloneJet vector. The
two most likely exonic off-target sites for sgK12LP in the mouse
genome, as predicted by the Zhang Lab online tool (http://crispr.
mit.edu) were assessed in the same way, where 10 colonies were
selected for analysis for each predicted off target. The predicted
off-target sites were 5′-TAAGTAGCTGATCTATCAGTGGG-3′ (Gon4l)
and 5′-TGGGAAGCATATCTGTCATTTGG-3′ (Asphd1). Only these
two sites were selected, as they were the only two to have a
calculated off-target score 40.1.
Statistics
All error bars represent the s.e.m. unless stated otherwise.
Signiﬁcance was calculated using an unpaired t-test, as all samples
demonstrated the same distribution. Statistical signiﬁcance was
set at 0.05%. Variance was calculated among groups and deemed
to be similar.
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